Announcement on Termination of Outward Investment
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Nanjing Pharmaceutical Group Company Limited has announced the termination of its outward investment in Ningbo Jiangfeng Biological Information Technology Co., Ltd.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Nanjing Pharmaceutical Group Company Limited on 6ix
Earlier from Nanjing Pharmaceutical
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Resolutions of the 2025 Annual General Meeting
- Report for Q1 2026
- Announcement on Issuance Result of Phase VI Ultra-Short-Term Financing Bonds of 2026
- Announcement on Progress in Government’s Expropriation of Certain Real Estate and Land of the Company’s Tier-II Subsidiary
Later from Nanjing Pharmaceutical
- Announcement on Resolutions of the Extraordinary Meeting of the 10th Board of Directors
- Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
- Announcement on Issuance Result of Phase I Medium-term Notes of 2026
- Announcement on Issuance Result of Phase VII Ultra-Short-Term Financing Bonds of 2026
- Announcement on the Redemption upon Maturity of Cash Management with Part of Temporarily Idle Raised Funds by the Company and the Continuation of Cash Management
Follow Nanjing Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing Pharmaceutical